GlaxoSmithKline (GB:GSK) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline’s Blenrep combinations for treating relapsed multiple myeloma have been accepted for review by the US FDA, supported by promising results from the DREAMM-7 and DREAMM-8 trials. These trials showed significant improvements in progression-free survival and overall survival, potentially redefining treatment options for this challenging cancer. A decision from the FDA is anticipated by July 2025.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.